The Software Maintenance Plan covers problem and modification analysis, modification implementation, system release, and migration/retirement. It bridges the gap between design controls and post-market software changes. IEC 62304 clause 6 requires the plan to cover how feedback is received and evaluated, how problems are reported and resolved, how changes are analyzed for safety impact, and how software of unknown provenance (SOUP) is monitored and updated. The plan should connect to complaint handling, CAPA, change control and cybersecurity vulnerability management, so that every update is assessed for regulatory impact before release.

Why it matters

A robust maintenance plan is what makes Letter-to-File decisions defensible and prevents post-market changes from becoming new submissions.

Common pitfalls

•A common pitfall is treating the Software Maintenance Plan as a static document rather than a living one that evolves with the software and regulatory landscape.
•Failing to adequately define criteria for determining when a software change necessitates a new regulatory submission instead of a Letter to File is a frequent mistake.
•Underestimating the resources, both human and technical, required to execute the maintenance plan effectively can lead to non-compliance and product issues.
•Another pitfall is not integrating cybersecurity maintenance activities, such as vulnerability management and patch deployment, directly into the Software Maintenance Plan.
•Neglecting to establish clear processes for documenting and verifying all software changes made under the maintenance plan can lead to audit findings.

Sources

IEC 62304 · IEC
FDA - AI/ML-Enabled Medical Devices · FDA
IMDRF - Software as a Medical Device · IMDRF

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.